| Expression pattern: |
DN |
| Associated gene: |
SF3A3, PRMT5, MDM4-S, p53 |
| Associated microRNA: |
miR-365b-3p |
| Biological function: |
inhibits proliferation; inhibits migration; promotes apoptosis; suppresses tumor growth/malignance |
| Molecular mechanism: |
circSCAP binds SF3A3 and promotes its ubiquitin-proteasome-mediated degradation, increases MDM4-S alternative splicing and activates downstream p53 signaling; also sponges miR-365b-3p but not functionally through it |
| Biological pathway or process: |
p53 signaling (promotes); proliferation (inhibits); migration (inhibits); apoptosis (promotes); cell cycle (inhibits); ubiquitination (promotes) |
| Detected method: |
Q
B
M
|
| Validation methods: |
Microarray; RT-qPCR; Northern Blot; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Clinical Sample Validation; Survival Analysis; ROC Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; Western Blot; Co-IP; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry) |
| Clinical significance: |
Low circSCAP level is associated with poor prognosis; circSCAP is an independent prognostic factor and a robust biomarker for prognosis evaluation in lung cancer |
| Description: |
circSCAP (hsa_circ_0065214), derived from SCAP, is down-regulated in lung cancer/NSCLC and acts as a tumor suppressor. It binds SF3A3 and promotes SF3A3 ubiquitin-proteasome degradation, increasing MDM4-S and activating p53 signaling to inhibit proliferation/migration and promote apoptosis. Higher circSCAP expression is associated with better patient prognosis and has prognostic biomarker potential. |
| Confidence score: |
0.8913 |